Andrew Schally
| Category | Research |
|---|---|
| Also known as | Andrzej Wiktor Schally |
| Last updated | 2026-04-14 |
| Reading time | 3 min read |
| Tags | scientisthypothalamic-hormonesnobel-prizeGnRHTRH |
Overview
Andrzej Wiktor "Andrew" Schally (born November 30, 1926) is a Polish-American endocrinologist who shared the 1977 Nobel Prize in Physiology or Medicine with Roger Guillemin and Rosalyn Yalow for the isolation of peptide hormones from the hypothalamus. Working primarily at Tulane University and later at the Veterans Affairs Medical Center in New Orleans, Schally's laboratory was a powerhouse of peptide discovery for several decades.
Schally's group isolated thyrotropin releasing hormone (in parallel competition with Guillemin) and gonadotropin releasing hormone, also called LHRH. Subsequent work generated clinically important analogs ā agonists and antagonists ā of LHRH for cancer and reproductive medicine, as well as analogs of somatostatin, growth hormone releasing hormone, and more recently bombesin.
Schally's career is notable for its longevity and breadth. Into his tenth decade, he remained active in research, producing analogs of hypothalamic peptides intended for oncology applications, including receptor-targeted cytotoxic conjugates.
Background
Schally was born in Wilno (then Poland, now Vilnius, Lithuania). His family fled Poland during World War II and he spent much of his youth in Romania, France, and Scotland before coming to Canada and then the United States. He earned his Ph.D. in endocrinology from McGill University in 1957 and joined Baylor College of Medicine, where he briefly overlapped with Guillemin before a fractious separation.
Schally established his own laboratory at Tulane in 1962 and led an industrial-scale effort to isolate hypothalamic peptides from pig hypothalami. His laboratory's output of characterized peptides and analogs over subsequent decades is among the largest of any single investigator in neuroendocrinology.
Key Contributions
- Isolation of TRH (1969, in parallel with Guillemin).
- Isolation of LHRH/GnRH (1971).
- Development of LHRH agonists and antagonists now used in prostate cancer, endometriosis, IVF, and precocious puberty.
- Somatostatin and GHRH analog development.
- Cytotoxic peptide conjugates for tumor-targeted therapy.
Timeline
- 1926: Born in Wilno (then Poland).
- 1957: Ph.D. from McGill University.
- 1962: Establishes laboratory at Tulane.
- 1969: Reports TRH structure.
- 1971: Reports LHRH structure.
- 1977: Shares Nobel Prize.
- 1980sā2020s: Continued development of hypothalamic peptide analogs and cytotoxic conjugates.
Modern Relevance
Schally's analogs of LHRH, including leuprolide and goserelin (agonists) and degarelix and relugolix (antagonists), are widely used in oncology and reproductive medicine. Somatostatin analogs developed along related lines underpin treatment of acromegaly and neuroendocrine tumors. The tumor-targeted cytotoxic conjugates developed by Schally's group, which link cytotoxins to peptide analogs that bind receptors overexpressed on cancer cells, anticipated modern peptide drug conjugates.
Schally's productivity ā more than 2,000 peer-reviewed publications ā makes him one of the most prolific biomedical scientists of the twentieth century. For broader context, see roger-guillemin and nobel-prize-hypothalamic-hormones.
Related Compounds
Related entries
- The 1977 Nobel Prize for Hypothalamic Hormonesā Roger Guillemin and Andrew Schally shared half of the 1977 Nobel Prize for isolating TRH, GnRH, and other hypothalamic peptide hormones.
- Roger Guilleminā Roger Guillemin was a French-American neuroendocrinologist who isolated TRH, GnRH, and somatostatin, sharing the 1977 Nobel Prize.
- The Discovery of Somatostatinā Somatostatin, the hypothalamic peptide that inhibits growth hormone release, was identified in 1973 by Brazeau and Guillemin.